Olema Oncology, Inc. (OLMA)
| Market Cap | 644.78M +16.5% |
| Revenue (ttm) | n/a |
| Net Income | -235.95M |
| EPS | -2.40 |
| Shares Out | 87.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,139,722 |
| Open | 7.48 |
| Previous Close | 7.56 |
| Day's Range | 7.08 - 7.73 |
| 52-Week Range | 6.24 - 36.26 |
| Beta | 2.02 |
| Analysts | Strong Buy |
| Price Target | 35.50 (+382.34%) |
| Earnings Date | Nov 10, 2026 |
About OLMA
Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $35.5, which is an increase of 382.34% from the latest price.
News
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Olema Oncology Announces Corporate Name Change
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company foc...
Olema Oncology Transcript: Stifel 2026 Healthcare Conference 2026
OPERA-01 is expected to read out in Q1, testing phase II results in ESR1-mutant and wild-type disease; OPERA-02 enrollment is robust, with a possible sample-size increase after December control-arm data. Launch preparations target mid-2028, subject to OPERA-01 results.
Olema Oncology price target lowered to $13 from $18 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Olema Oncology (OLMA) to $13 from $18 and keeps a Buy rating on the shares following the Q3 results. Goldman sees a…
Olema Oncology reports Q3 EPS (73c), consensus (63c)
“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine…
Olema Oncology Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
OPERA-01 top-line results are expected in Q1 2027, with separate ESR1-mutant and wild-type outcomes. OPERA-02 may expand depending on control-arm performance, while San Antonio will feature palazestrant combinations and OP-3136 data.
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Oncology Earnings release: Q3 2026
Olema Oncology released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Olema Oncology Quarterly report: Q3 2026
Olema Oncology has published its Q3 2026 quarterly earnings report on November 10, 2026.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Oncology Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Palazestrant is advancing in two phase III trials for ER+, HER2- breast cancer, targeting both ESR1 mutant and wild-type populations, with a key readout expected in Q1 2027. OP-3136, a KAT6 inhibitor, is progressing in breast and prostate cancer, with new combination data anticipated next year.
Olema Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Palazestrant stands out among oral SERDs due to its complete antagonism, high exposure, and unique combinability, with phase III trials targeting both mutant and wild type ESR1 populations. The KAT6 inhibitor pipeline expands opportunities in breast and prostate cancer, supported by strong financials and multiple upcoming catalysts.
Olema Oncology price target lowered to $30 from $48 at Stifel
Stifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday that its…
Olema selloff on Astra miss ‘significant overreaction,’ says JPMorgan
JPMorgan analyst Anupam Rama keeps an Overweight rating on Olema Oncology (OLMA) after AstraZeneca (AZN) announced that the SERENA-4 study in patients with ER+/HER2- advanced breast cancer missed stat...
Olema selloff on AstraZeneca miss a buying opportunity, says Citi
Citi views the pullback in Olema Oncology (OLMA) after AstraZeneca (AZN) announced the camizestrant plus palbociclib combination did not meet the primary endpoint as a buying opportunity. Astra’s SERE...
Olema Oncology Transcript: Citigroup’s Biopharma Back to School Summit 2026
Palazestrant is advancing in two phase III breast cancer trials, targeting both ESR1 mutant and wild-type populations, with top-line data for OPERA-01 expected in Q1 2027 and significant commercial potential. Additional pipeline assets, including a KAT6 inhibitor, are progressing in breast and prostate cancer, while AI is streamlining operations.
Olema Oncology price target lowered to $46 from $52 at JPMorgan
JPMorgan lowered the firm’s price target on Olema Oncology (OLMA) to $46 from $52 and keeps an Overweight rating on the shares.
Olema Oncology appoints Jason O’Byrne as CFO
Olema (OLMA) announced the appointment of Jason O’Byrne as CFO. O’Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology and pharmaceutical org...
Olema Oncology price target lowered to $20 from $23 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Olema Oncology (OLMA) to $20 from $23 and keeps a Buy rating on the shares. Olema’s Q2 update extended its cash runway…
Olema Oncology price target lowered to $59 from $62 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Olema Oncology (OLMA) to $59 from $62 and keeps a Buy rating on the shares.
Olema Oncology price target lowered to $36 from $38 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Olema Oncology (OLMA) to $36 from $38 and keeps a Buy rating on the shares post the Q2 report. OPERA-01 topline data…
Olema Oncology reports Q2 EPS (61c), consensus (56c)
“Our commitment to transforming the metastatic breast cancer treatment paradigm remains resolute as we continue to advance palazestrant as a potentially differentiated endocrine therapy across multipl...
Olema Oncology Earnings release: Q2 2026
Olema Oncology released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Olema Oncology Quarterly report: Q2 2026
Olema Oncology has published its Q2 2026 quarterly earnings report on August 10, 2026.